Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05338762 · ClinicalTrials.gov registry record

TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood

A clinical trial of SARS-CoV2 Infection, sponsored by MiCo BioMed Co..

Completed
Registry status
218
Enrollment target
5
Study locations

NCT05338762 is a study of SARS-CoV2 Infection that has completed, run by MiCo BioMed Co.. The registered enrollment target is 218 participants, below the 1,221-participant average among 6 other SARS-CoV2 Infection trials with a reported enrollment target (82% lower). The trial reports 5 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05338762, a study of SARS-CoV2 Infection, has completed, sponsored by MiCo BioMed Co..

COMPLETED
Registry status
218 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to determine if the TekiTrust Enzyme-Linked Immunosorbent Assay (ELISA) Kit and TekiTrust Rapid Test can accurately determine the amount of antibodies to fight the COVID-19 virus in sampled blood compared to the standard Plaque Reduction Neutralization Test (PRNT) test. When a person has COVID-19 they develop antibodies to the virus which are contained in their blood stream. After a certain period, the number of antibodies to fight (neutralize) the virus begin to decrease. One common way to measure the amount of antibodies in the blood is to use a test called the PRNT. The focus of this study is to compare the ability of the TekiTrust ELISA Kit and the TekiTrust Rapid Test with the PRNT to determine if these tests can measure the antibodies equally well.

Conditions Studied

SARS-CoV2 Infection

Study Locations (5)

Ohio

  • WellNow Urgent Care - Cincinnati
  • WellNow Urgent Care - Columbus
  • WellNow Urgent Care - Dayton

Mississippi

  • Mississippi State University - Starkville

New Jersey

  • Joy Internal Medicine - Englewood Cliffs

Trial Details

FieldValue
Enrollment Target 218 participants
Start Date 2021-06-02
Est. Completion 2022-08-03

Sponsor

MiCo BioMed Co.

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05338762

The ClinicalTrials.gov registry entry for NCT05338762 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,221-participant average among 6 other SARS-CoV2 Infection trials with a reported enrollment target (82% lower). The listed sponsor is MiCo BioMed Co., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with SARS-CoV2 Infection appearing as the primary indexed condition, and to 0 interventions.

NCT05338762 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Ohio, Mississippi, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05338762 about?

NCT05338762 is a clinical study titled "TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood". The purpose of this study is to determine if the TekiTrust Enzyme-Linked Immunosorbent Assay (ELISA) Kit and TekiTrust Rapid Test can accurately determine the amount of antibodies to fight the COVID-19 virus in sampled blood compared to the standard Plaque Reduction Neutralization Test (PRNT) test. ...

What is the current status of trial NCT05338762?

This trial is currently completed. The enrollment target is 218 participants. The study started on 2021-06-02. Estimated completion is 2022-08-03.

What conditions does trial NCT05338762 study?

This clinical trial studies the following conditions: SARS-CoV2 Infection.

Who is sponsoring clinical trial NCT05338762?

This trial is sponsored by MiCo BioMed Co., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05338762 being conducted?

This trial has 5 study locations across Mississippi, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for SARS-CoV2 Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

SARS-CoV2 Infection

All registered trials for this condition

Mississippi

All trials with a study site in Mississippi

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.